RADNOR,
Pa., May 10, 2023 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a clinical-stage biopharmaceutical company, today
announced that it is rescheduling its first quarter quarterly
investor conference call previously scheduled for Thursday, May 11, 2023 at 4:30pm ET to Tuesday, May
16, 2023 at 8:30am ET, due to
scheduling conflicts. The Company's first quarter 2023 earnings
press release is expected to be issued on the morning of
May 16, 2023, followed by an investor
conference call hosted by management at 8:30am ET that day.
A live webcast of the conference call will be available on the
Company's website
at https://ir.nrxpharma.com/news-events/ir-calendar. An
archive of the webcast will be available on the Company's website
for 30 days.
Participants that are unable to join the webcast can access the
conference call via telephone by dialing domestically +1 (833)
630-1956 or internationally +1 (412) 317-1837.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics for the treatment of central
nervous system disorders, specifically bipolar depression with
suicidality and post-traumatic stress disorder (PTSD). The
company's lead program NRX-101, an oral, fixed-dose combination of
D-cycloserine and lurasidone, targets the brain's
N-methyl-D-aspartate (NMDA) receptor and is being investigated in a
Phase 2b/3 clinical trial for
suicidal treatment-resistant bipolar depression, which includes
patients with both acute and sub-acute suicidality, an indication
for which the only approved treatment is electroshock therapy. The
company's prior Phase 2 STABIL-B clinical trial evaluating NRX-101
in patients with Severe Bipolar Depression with Acute Suicidal
Ideation & Behavior (ASIB) demonstrated a substantial
improvement over available therapy in reducing depression and
suicidality compared to placebo when patients were treated with
NRX-101 after a single dose of ketamine. Based on the findings from
the STABIL-B trial, the U.S. Food and Drug Administration (FDA)
granted a Special Protocol Agreement and Breakthrough Therapy
Designation for NRX-101 in patients with Severe Bipolar Depression
with ASIB.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-reschedules-first-quarter-2023-financial-results-conference-call-301821402.html
SOURCE NRx Pharmaceuticals, Inc.